Clinical trial
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 26, 2014
- Completion date
- December 31, 2027
- Enrollment
- 982 (actual)
- Sites
- 173
Conditions
As the registry lists them; a condition with its own page is linked.